Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model
References (20)
- et al.
Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals
Brain Res. Bull.
(2003) - et al.
Sexual differences in onset of disease and response to exercise in a transgenic model of ALS
Neuromuscul. Disord.
(2003) - et al.
Emerging biological roles for erythropoietin in the nervous system
Nat. Rev., Neurosci.
(2005) - et al.
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Proc. Natl. Acad. Sci. U. S. A.
(2000) - et al.
Unraveling the mechanisms involved in motor neuron degeneration in ALS
Annu. Rev. Neurosci.
(2004) - et al.
Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury
Proc. Natl. Acad. Sci. U. S. A.
(2002) - et al.
Prognosis in amyotrophic lateral sclerosis: a population-based study
Neurology
(2003) - et al.
Erythropoietin therapy for acute stroke is both safe and beneficial
Mol. Med.
(2002) - et al.
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo
Proc. Natl. Acad. Sci. U. S. A.
(2003) - et al.
Gender-related differences in recovery of locomotor function after spinal cord injury in mice
Spinal Cord
(2006)
Cited by (43)
Sex biology in amyotrophic lateral sclerosis
2024, Ageing Research ReviewsRecent approaches to target apoptosis in neurological disorders
2021, Clinical Perspectives and Targeted Therapies in Apoptosis: Drug Discovery, Drug Delivery, and Disease PreventionLentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6/2 mouse model of Huntington's disease
2020, Neurobiology of DiseaseCitation Excerpt :In the adult CNS, the cytokine erythropoietin (EPO) is involved in maintaining neuronal survival and cell proliferation (Digicaylioglu et al., 1995; Shingo et al., 2001; Chen et al., 2007). The application of recombinant human EPO (hEPO) has been shown to improve learning and memory in rodent models of depression, cerebral ischemia, and traumatic brain injury (Lu et al., 2005; Zhang et al., 2007; Girgenti et al., 2009; Leconte et al., 2011), and hEPO attenuates disease progression in a mouse model of amyotrophic lateral sclerosis (Grunfeld et al., 2007). In humans, the neurotrophic properties of EPO on cognitive function are also evident in diseases such as schizophrenia and multiple sclerosis (Ehrenreich et al., 2007; Wüstenberg et al., 2011).
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs
2018, Journal of Controlled ReleaseCitation Excerpt :The EPO and their receptors seem to get stimulated by any nerve injury and neurodegeneration [264]. Moreover, EPO injection was found to improve the brain damage and neuronal function in various experimental brain disorders, including: a) brain haemorrhage [265], b) cerebral ischemia [266,267], c) spinal cord injury [268], d) traumatic brain injury [269], e) autoimmune encephalitis [270], f) epilepsy [262], g) neonatal hypoxia-ischemia [271] and amyotrophic lateral sclerosis [272]. At the same time, there is also some evidence from both, the in vitro and in vivo AD models available that confirms the neuroprotective effect of EPO against Aβ neurodegeneration [273,274].
Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research
2010, Best Practice and Research: Clinical AnaesthesiologyCitation Excerpt :In the category neurodegeneration, models of epilepsy, Parkinson’s disease, retinal degeneration, peripheral neuropathy in general and diabetic neuropathy in particular, sciatic nerve injury, amyotrophic lateral sclerosis, and other, rarer conditions are listed. Over 60 studies have been published in this field.14,39,40,53,58,61,79,137–191 Again, many of them report increased/prolonged survival rates, improved neurological outcome, and amelioration of specific symptoms or even recovery, coupled with reduction in inflammation, blood–brain barrier leakage, apoptosis and demyelination/nerve fiber loss.
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells
2010, BloodCitation Excerpt :The reported cytoprotective activity of rHuEpo in rat spinal cord compression and contusion injury models49 was not reproduced by others.19 Conflicting cytoprotective findings have been reported with ESAs in murine models of amyotrophic lateral sclerosis,50,51 and rHuEpo did not provide neuroprotection in a rabbit bacterial meningitis model.18 A recent study found no effect of rHuEpo on hepatocytes in vitro and concluded reports of in vivo liver cytoprotective effects were via indirect mechanisms.52